Tenax Therapeutics Inc YBOC-FF:Frankfurt Stock Exchange

RT Quote | Exchange | EUR
Last | 9:23 AM CEST
0.58quote price arrow down-0.04 (-6.45%)
52 week range
0.43 - 1.84
Loading...
  • Open0.58
  • Day High0.58
  • Day Low0.58
  • Prev Close0.958
  • 52 Week High1.84
  • 52 Week High Date06/29/21
  • 52 Week Low0.43
  • 52 Week Low Date03/15/22

Key Stats

  • Market Cap16.03M
  • Shares Out25.21M
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-32.71

KEY STATS

  • Open0.58
  • Day High0.58
  • Day Low0.58
  • Prev Close0.958
  • 52 Week High1.84
  • 52 Week High Date06/29/21
  • 52 Week Low0.43
  • 52 Week Low Date03/15/22
  • Market Cap16.03M
  • Shares Out25.21M
  • 10 Day Average Volume-
  • Dividend-
  • Dividend Yield-
  • Beta-
  • YTD % Change-32.71

RATIOS/PROFITABILITY

  • EPS (TTM)-1.79
  • P/E (TTM)-0.32
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Tenax Therapeutics Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Tenax Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying and developing therapeutics that address cardio-pulmonary diseases with high unmet medical need. The Company's products include TNX-103 (oral levosimendan) and TNX-201 (oral enteric coated imatinib). The Company's lead product, Levosimendan, is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. TNX-201 is for...
Gerald Proehl
Independent Chairman of the Board
Christopher Giordano
President, Chief Executive Officer, Director
Eliot Lurier CPA
Interim Chief Financial Officer
Address
One Copley Parkway, Suite 490
Morrisville, NC
27560
United States